Nowadays, a novel monovalent anti-FcγRIII/albumin fusion protein has been generated to alleviate platelet destruction without the side effects caused by the FcγR-specific antibody in the ITP murine model (68). This evidence concerns the gene FCGR2A and autoimmune thrombocytopenic purpura.